-
Subject Areas on Research
-
3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia.
-
49th Annual Meeting of the American Academy of Child & Adolescent Psychiatry. 22-27 October 2002, San Francisco, CA, USA.
-
A Pharmacy-Based Electronic Handoff Tool to Reduce Discharge Prescribing of Atypical Antipsychotics Initiated in the Intensive Care Unit: A Quality Improvement Initiative.
-
A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.
-
A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial.
-
A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia.
-
A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder.
-
A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients.
-
A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).
-
A new method for studying the interaction between chlorpromazine and phospholipid bilayer.
-
A perilous disconnect: antipsychotic drug use in very young children.
-
A pilot randomized placebo-controlled trial of adjunctive aripiprazole for chronic PTSD in US military Veterans resistant to antidepressant treatment.
-
A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder.
-
A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder.
-
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
-
A randomized trial of a consultation service to reduce falls in nursing homes.
-
A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
-
A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia.
-
A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies.
-
A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia.
-
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.
-
A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus.
-
A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder.
-
A+KIDS, a web-based antipsychotic registry for North Carolina youths: an alternative to prior authorization.
-
ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia.
-
Acute dystonic reaction with moderate-dose ziprasidone.
-
Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs.
-
Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.
-
Adjunctive brexpiprazole for the treatment of major depressive disorder.
-
Adjunctive use of olanzapine in mood disorders: five case reports.
-
Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder.
-
Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia.
-
Amisulpride Prevents Postoperative Nausea and Vomiting in Patients at High Risk: A Randomized, Double-blind, Placebo-controlled Trial.
-
An assessment of the understanding and motivations of patients with schizophrenia about participating in a clinical trial.
-
An empirical analysis of cost outcomes of the Texas Medication Algorithm Project.
-
An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder.
-
An open-label pilot study of aripiprazole for male and female veterans with chronic post-traumatic stress disorder who respond suboptimally to antidepressants.
-
An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction.
-
An overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
-
An overview of the clinical rationale for advancing gender-related psychopharmacology and drug abuse research.
-
An unsubstantiated conclusion.
-
Angioedema occurring in patient prescribed iloperidone and haloperidol: a cross-sensitivity reaction to antipsychotics from different chemical classes.
-
Anticipating DSM-V: opportunities and challenges for cognition and psychosis.
-
Antipsychotic Use Is Associated With Longer In-hospital Lengths of Stay and Higher Rates of Venous Thromboembolism and Costs of Care After Primary Total Knee Arthroplasty.
-
Antipsychotic drug effects on brain morphology in first-episode psychosis.
-
Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.
-
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.
-
Antipsychotic medications and sudden cardiac death.
-
Antipsychotic-induced weight gain and therapeutic response: a differential association.
-
Antipsychotics and dementia: where do we go from here?
-
Antipsychotics and sudden death: is thioridazine the only bad actor?
-
Antipsychotics and the risk of sudden cardiac death.
-
Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignant syndrome.
-
Aripiprazole: pharmacology, efficacy, safety and tolerability.
-
Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
-
Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial.
-
Atypical antidopaminergic properties of CI-686: a potential antipsychotic agent.
-
Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study.
-
Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis.
-
Atypical antipsychotic drugs and hyperglycemia in adolescents.
-
Atypical antipsychotics and pituitary neoplasms in the WHO database.
-
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
-
Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents.
-
Barriers to employment for people with schizophrenia.
-
Bipolar Depression: Pregnancy, Postpartum, and Lactation.
-
Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
-
Body mass index and future schizophrenia in Israeli male adolescents.
-
Brain stem as a target site for the metabolic side effects of olanzapine.
-
Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients.
-
COMT158 polymorphism and hostility.
-
COVID-19-associated brief psychotic disorder.
-
Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial.
-
Cardiometabolic Assessment, Diagnosis, and Treatment of Chronic Medical Illnesses During an Inpatient Psychiatric Hospitalization: Colocated Medical Care Versus Treatment as Usual.
-
Case report: possible neuroleptic malignant syndrome associated with olanzapine.
-
Caspase-3 activation in rat frontal cortex following treatment with typical and atypical antipsychotics.
-
Caudate hyperintensities in elderly depressed patients with neuroleptic-induced parkinsonism.
-
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.
-
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
-
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.
-
Characteristics of antipsychotic medication prescribing on inpatient obstetric floors.
-
Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
-
Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature.
-
Chronic neuroleptic effects on spatial reversal learning in monkeys.
-
Chronic neuroleptics alter the effects of the D1 agonist SK&F 38393 and the D2 agonist LY171555 on oral movements in rats.
-
Chronic nicotine and dizocilpine effects on nicotinic and NMDA glutamatergic receptor regulation: interactions with clozapine actions and attentional performance in rats.
-
Chronic nicotine interactions with clozapine and risperidone and attentional function in rats.
-
Chronic underactivity of medial frontal cortical beta2-containing nicotinic receptors increases clozapine-induced working memory impairment in female rats.
-
Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies.
-
Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center.
-
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.
-
Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania.
-
Clinician ratings vs. global ratings of symptom severity: a comparison of symptom measures in the bipolar disorder module, phase II, Texas Medication Algorithm Project.
-
Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy?
-
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
-
Clozapine treatment reverses dizocilpine-induced deficits of pre-pulse inhibition of tactile startle response.
-
Clozapine-induced electroencephalogram changes as a function of clozapine serum levels.
-
Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation.
-
Cognition in schizophrenia: summary Nice Consultation Meeting 2012.
-
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).
-
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.
-
Cognitive effects of quetiapine XR in patients with euthymic bipolar disorder.
-
Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness.
-
Cognitive impairment as a target for pharmacological treatment in schizophrenia.
-
Cognitive impairment in schizophrenia.
-
Comment on Nasrallah et al: lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol.
-
Comments on "Addition of lamotrigine to valproic acid: a successful outcome in a case of rapid-cycling bipolar affective disorder".
-
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
-
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
-
Comparative mortality risks of antipsychotic medications in community-dwelling older adults.
-
Comparison of academic and nonacademic sites in multi-center clinical trials.
-
Comparison of adaptive treatment strategies based on longitudinal outcomes in sequential multiple assignment randomized trials.
-
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia.
-
Comparison of outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE study.
-
Concealed medicines for people with schizophrenia: a U.S. perspective.
-
Continuation of clozapine during chemotherapy: a case report and review of literature.
-
Continuity of antipsychotic medication management for Medicaid patients with schizophrenia.
-
Correlates of Future Violence in People Being Treated for Schizophrenia.
-
Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.
-
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
-
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol.
-
Criminal justice system involvement among people with schizophrenia.
-
Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia.
-
D2 Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine.
-
Decision model for the acute treatment of mania.
-
Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial.
-
Deletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action.
-
Delirium in older persons.
-
Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.
-
Determination of sulpiride by capillary electrophoresis with end-column electrogenerated chemiluminescence detection.
-
Diet and the atypical neuroleptics.
-
Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig.
-
Difficult behaviors in long-term care patients with dementia.
-
Difficult behaviors in long-term care patients with dementia.
-
Discharge Plans for Geriatric Inpatients with Delirium: A Plan to Stop Antipsychotics?
-
Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy.
-
Distinct cortical and striatal actions of a β-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties.
-
Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial.
-
Does sigma receptor antagonism predict clinical antipsychotic efficacy?
-
Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial.
-
Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.
-
Drug and alcohol trajectories among adults with schizophrenia: data from the CATIE study.
-
Drug rash with eosinophilia and systemic symptoms (DRESS syndrome).
-
Drugs of the psychopharmacological revolution in clinical psychiatry.
-
Dual Health Care System Use and High-Risk Prescribing in Patients With Dementia: A National Cohort Study.
-
Dual Health Care System Use and Unsafe Medication Prescribing in Veterans With Dementia.
-
Dynamics of lip dyskinesia associated with neuroleptic withdrawal.
-
Early Recognition of Preventable Factors Associated with Delirium Saves Lives and Costs.
-
Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis.
-
Eating disorders.
-
Effect of Medicaid Policy Changes on Medication Adherence: Differences by Baseline Adherence.
-
Effect of a mental health "carve-out" program on the continuity of antipsychotic therapy.
-
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
-
Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment.
-
Effectiveness of atypical antipsychotics for substance use in schizophrenia patients.
-
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
-
Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.
-
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
-
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
-
Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.
-
Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.
-
Effectiveness of switching from antipsychotic polypharmacy to monotherapy.
-
Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.
-
Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia.
-
Effects of amphetamines and small related molecules on recovery after stroke in animals and man.
-
Effects of antipsychotic medication on psychiatric service utilization and cost.
-
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
-
Effects of antipsychotic medications on sleep in schizophrenia.
-
Effects of antipsychotic withdrawal in elderly nursing home residents.
-
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
-
Effects of classical and atypical antipsychotic drugs on isolation-induced aggression in male mice.
-
Effects of clozapine on memory function in the rat neonatal hippocampal lesion model of schizophrenia.
-
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
-
Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.
-
Effects of involuntary outpatient commitment and depot antipsychotics on treatment adherence in persons with severe mental illness.
-
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
-
Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.
-
Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice.
-
Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis.
-
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
-
Efficacy of Transcendental Meditation to Reduce Stress Among Health Care Workers: A Randomized Clinical Trial.
-
Efficacy of olanzapine in social anxiety disorder: a pilot study.
-
Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis.
-
Efficacy of risperidone on positive features of schizophrenia.
-
Electrocardiogram Characteristics and Their Association With Psychotropic Drugs Among Patients With Schizophrenia.
-
Electronic monitoring of antipsychotic medication adherence in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of its reliability and predictive validity.
-
Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
-
Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.
-
Estimating suicidality as an outcome measure in clinical trials of suicide in schizophrenia.
-
Evaluation of Risk Factors for Antipsychotic Polypharmacy in Inpatient Psychiatry Units of a Community Hospital: A Retrospective Analysis.
-
Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial.
-
Evaluation of the effects of diazepam and an experimental anti-anxiety drug on regional cerebral blood flow.
-
Examination of QTc Values in Critically Ill Patients Diagnosed with Delirium and Prescribed Atypical Antipsychotics.
-
Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.
-
Examining Parental Medication Adherence as a Predictor of Child Medication Adherence in Pediatric Anxiety Disorders.
-
Examining the relationship between adjunctive psychotherapy use and antipsychotic persistence and hospitalization.
-
Extrapyramidal side-effects of antipsychotics in a randomised trial.
-
Feasibility of myelosuppressive chemotherapy in psychiatric patients on clozapine: A systematic review of the literature.
-
First- and second-generation antipsychotics.
-
First-line pharmacotherapy approaches for generalized anxiety disorder.
-
Frequency of high-risk use of QT-prolonging medications.
-
GERI-BD: A Randomized Double-Blind Controlled Trial of Lithium and Divalproex in the Treatment of Mania in Older Patients With Bipolar Disorder.
-
Genetic correlates of insight in schizophrenia.
-
Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study.
-
Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.
-
Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs.
-
Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
-
Haase hermeneutics, or, the exegesis of the neuroleptic threshold.
-
Haloperidol for the management of delirium in adult intensive care unit patients: A systematic review and meta-analysis of randomized controlled trials.
-
Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications.
-
High-Deductible Health Plans Paired With Health Savings Accounts Increased Medication Cost Burden Among Individuals With Bipolar Disorder.
-
High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study.
-
Histamine H1 receptor involvement in prepulse inhibition and memory function: relevance for the antipsychotic actions of clozapine.
-
Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia.
-
IQ scores of treatment-resistant schizophrenia patients before and after the onset of the illness.
-
Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment.
-
Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial.
-
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.
-
Impact of neuroleptic medications on continuous performance test measures in schizophrenia.
-
Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder.
-
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.
-
Implications of atypical antipsychotic prescribing in the intensive care unit.
-
In Vitro and In Vivo Characterization of the Alkaloid Nuciferine.
-
Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.
-
Inpatient and outpatient patterns of psychotropic drug prescribing by nonpsychiatrist physicians.
-
Insight in first-episode psychosis.
-
Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol.
-
Intravenous ziprasidone for treatment of delirium in the intensive care unit.
-
Introduction to the CATIE special section.
-
Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia.
-
Kraepelinian schizophrenia: a subgroup of schizophrenia?
-
L-dopa challenge and relapse in schizophrenia.
-
Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials.
-
Latent class analysis of discordance between results of drug use assessments in the CATIE data.
-
Lefetamine: new abuse of an old drug--clinical evaluation of opioid activity.
-
Life-Course Persistent Antisocial Behavior and Accelerated Biological Aging in a Longitudinal Birth Cohort.
-
Lithium for the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled Discontinuation Study.
-
Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium.
-
Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia.
-
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.
-
Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study.
-
Measurements of plasma homovanillic acid in schizophrenic patients.
-
Measuring outcome priorities and preferences in people with schizophrenia.
-
Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care.
-
Medication compliance.
-
Medication nonadherence and substance abuse in psychotic disorders: impact of depressive symptoms and social stability.
-
Mental health care from the public perspective: the Texas Medication Algorithm Project.
-
Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.
-
Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.
-
Metabolic profiling of patients with schizophrenia.
-
Metabolomic mapping of atypical antipsychotic effects in schizophrenia.
-
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
-
Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders.
-
Methodological issues in developing new acute treatments for patients with bipolar illness.
-
Methodological issues in negative symptom trials.
-
Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder.
-
Multiple outcomes and analyses in clinical trials create challenges for interpretation and research synthesis.
-
N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity.
-
Neurobiochemical changes in tardive dyskinesia.
-
Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale.
-
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
-
Neuroleptic treatment and caudate plasticity.
-
Neuroleptic-induced oral movements in rats: methodological issues.
-
Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report.
-
Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study.
-
New Developments in Insomnia Medications of Relevance to Mental Health Disorders.
-
Nicotine and clozapine actions on pre-pulse inhibition deficits caused by N-methyl-D-aspartate (NMDA) glutamatergic receptor blockade.
-
Nicotine and clozapine effects on attentional performance impaired by the NMDA antagonist dizocilpine in female rats.
-
Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats.
-
Nicotine-antipsychotic drug interactions and attentional performance in female rats.
-
Nicotine-haloperidol interactions and cognitive performance in schizophrenics.
-
Nicotinic antagonist effects in the mediodorsal thalamic nucleus: regional heterogeneity of nicotinic receptor involvement in cognitive function.
-
Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.
-
Nicotinic-antipsychotic drug interactions and cognitive function.
-
Obesity among those with mental disorders: a National Institute of Mental Health meeting report.
-
Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents.
-
Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions.
-
Olanzapine and haloperidol in first episode psychosis: two-year data.
-
Olanzapine in PDD.
-
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
-
Olanzapine interactions with nicotine and mecamylamine in rats: effects on memory function.
-
Olanzapine on trial.
-
Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose.
-
Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature.
-
On sample size calculation based on odds ratio in clinical trials.
-
One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.
-
Onset of dyskinesia and changes in postural task performance during the course of neuroleptic withdrawal.
-
Open-label pilot study of ziprasidone for refractory generalized anxiety disorder.
-
Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.
-
Optimizing outcome with antipsychotic treatment in first-episode schizophrenia: balancing efficacy and side effects.
-
PCM1 is necessary for focal ciliary integrity and is a candidate for severe schizophrenia.
-
Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports.
-
Patients' Preferences Related to Benefits, Risks, and Formulations of Schizophrenia Treatment.
-
Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma.
-
Patterns of pharmacotherapy and treatment response in elderly adults with bipolar disorder.
-
Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
-
Performance of a weight-related measure of Quality of Life in a psychiatric sample.
-
Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.
-
Pharmacologic Intervention for the Treatment and Prevention of Delirium: Looking Beneath the Modeling.
-
Pharmacologic treatment of posttraumatic stress disorder: a focus on antipsychotic use.
-
Pharmacological agents to treat severe neuropsychiatric symptoms in major neurocognitive disorders.
-
Pharmacological management of first-episode schizophrenia and related nonaffective psychoses.
-
Pharmacological studies of a novel dopamine-sensitive receptor mediating burst-firing inhibition of neurosecretory cell R 15 in Aplysia californica.
-
Pharmacometabolomic signature of ataxia SCA1 mouse model and lithium effects.
-
Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology.
-
Pharmacotherapy of bipolar disorder in old age: review and recommendations.
-
Pharmacotherapy of impaired affect in recovering schizophrenic patients.
-
Pharmacotherapy of the Preschool ADHD Treatment Study (PATS) Children Growing Up.
-
Pharmacovigilance in the 21st century: new systematic tools for an old problem.
-
Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder.
-
Post-traumatic stress disorder: an evaluation of existing pharmacotherapies and new strategies.
-
Postoperative delirium: etiology and management.
-
Predicting antipsychotic use in children.
-
Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial.
-
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.
-
Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders.
-
Predictors of antipsychotic withdrawal or dose reduction in a randomized controlled trial of provider education.
-
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.
-
Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence.
-
Premorbid behavioral and intellectual functioning in schizophrenia patients with poor response to treatment with antipsychotic drugs.
-
Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States.
-
Prevalence of baseline lipid monitoring in patients prescribed second-generation antipsychotics during their index hospitalization: a retrospective cohort study.
-
Prevalence of celiac disease and gluten sensitivity in the United States clinical antipsychotic trials of intervention effectiveness study population.
-
Prioritization of research addressing antipsychotics for adolescents and young adults with bipolar disorder.
-
Progress in delirium.
-
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.
-
Prolactin-related and metabolic adverse effects of atypical antipsychotic agents.
-
Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.
-
Providers' Behaviors and Beliefs on Prescribing Antipsychotic Medication to Children: A Qualitative Study.
-
Psychiatrists' judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatment.
-
Psychopharmacological treatment for very young children: contexts and guidelines.
-
Psychotic disorder in a patient with central and extrapontine myelinolysis.
-
Psychotropic drug use in late life: a diverse look at an expanding field.
-
Psychotropic drugs on general medical and surgical wards of a teaching hospital.
-
QTc monitoring in adults with medical and psychiatric comorbidities: Expert consensus from the Association of Medicine and Psychiatry.
-
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode.
-
Quetiapine XR: current status for the treatment of major depressive disorder.
-
Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study.
-
Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings.
-
Quetiapine for the treatment of delirium.
-
Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study.
-
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.
-
Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
-
Real-world effectiveness of long-acting injectable antipsychotics to reduce 90-day and annual readmission in psychotic disorders: insights from a state psychiatric hospital.
-
Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.
-
Reducing antipsychotic drug prescribing for nursing home patients: a controlled trial of the effect of an educational visit.
-
Reducing polypharmacy: evidence from a simple quality improvement initiative.
-
Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone.
-
Relating Intrinsic Low-Frequency BOLD Cortical Oscillations to Cognition in Schizophrenia.
-
Relationship of cognition and psychopathology to functional impairment in schizophrenia.
-
Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy.
-
Reliabilities and intercorrelations of reported and objective measures of smoking in patients with schizophrenia.
-
Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale.
-
Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia.
-
Reproducibility probability in clinical trials.
-
Resting-state brain function in schizophrenia and psychotic bipolar probands and their first-degree relatives.
-
Results of phase 3 of the CATIE schizophrenia trial.
-
Reversal of clozapine effects on working memory in rats with fimbria-fornix lesions.
-
Revised PORT recommendations.
-
Risks versus benefits of different types of long-acting injectable antipsychotics.
-
Risperidone and cognitive function in children with disruptive behavior disorders.
-
Risperidone and explosive aggressive autism.
-
Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence.
-
Risperidone use in autism spectrum disorders: a retrospective review of a clinic-referred patient population.
-
Risperidone-associated diabetes mellitus: a pharmacovigilance study.
-
Safety and antipsychotic efficacy of "forced" intramuscular olanzapine over five days: a case report.
-
Schizophrenia, drug therapy, and monitoring.
-
Scopolamine interactions with D1 and D2 antagonists on radial-arm maze performance in rats.
-
Second-Generation Antipsychotics in Management of Acute Pediatric Bipolar Depression: A Systematic Review and Meta-analysis.
-
Sedation practices in a cohort of critically ill patients receiving prolonged mechanical ventilation.
-
Seizure threshold in electroconvulsive therapy: I. Initial seizure threshold.
-
Separation of promethazine and thioridazine using capillary electrophoresis with end-column amperometric detection.
-
Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol.
-
Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.
-
Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.
-
Sleep therapeutics and neuropsychiatric illness.
-
Sleepwalking and sleep-related eating associated with atypical antipsychotic medications: Case series and systematic review of literature.
-
Smoking and therapeutic response to clozapine in patients with schizophrenia.
-
Social support in late life mania: GERI-BD.
-
Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications.
-
Spine pruning drives antipsychotic-sensitive locomotion via circuit control of striatal dopamine.
-
Spirituality and religion in outpatients with schizophrenia: a multi-site comparative study of Switzerland, Canada, and the United States.
-
Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists.
-
Structured diagnostic assessment and depot fluphenazine treatment of multiple suicide attempters in the emergency department.
-
Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.
-
Substance use and schizophrenia: adverse correlates in the CATIE study sample.
-
Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study.
-
Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia.
-
Suicide attempts in veterans with bipolar disorder during treatment with lithium, divalproex, and atypical antipsychotics.
-
Suicide risk analysis among patients assigned to psychotropics and placebo.
-
Supportive approaches for Alzheimer disease.
-
Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan.
-
Symptom exacerbation in psychotically depressed adolescents due to high desipramine plasma concentrations.
-
Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy.
-
Temporal lobe volume in bipolar disorder: relationship with diagnosis and antipsychotic medication use.
-
Texas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms.
-
Texas Medication Algorithm Project: development and feasibility testing of a treatment algorithm for patients with bipolar disorder.
-
The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder.
-
The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.
-
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.
-
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?
-
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.
-
The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia.
-
The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms.
-
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.
-
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.
-
The Texas Medication Algorithm Project: development and implementation of the schizophrenia algorithm.
-
The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder.
-
The Texas medication algorithm project: clinical results for schizophrenia.
-
The Treatment of Behavioral and Psychological Symptoms of Dementia: Weighing Benefits and Risks.
-
The association between weight change and symptom reduction in the CATIE schizophrenia trial.
-
The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease.
-
The changing effector pattern of tardive dyskinesia during the course of neuroleptic withdrawal.
-
The changing perspective on chronic insomnia management.
-
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
-
The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial.
-
The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression.
-
The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.
-
The effects of medications on bone.
-
The effects of race and criminal justice involvement on access to atypical antipsychotic medications among persons with schizophrenia.
-
The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report.
-
The first clinical study of BW-234U in schizophrenia.
-
The impact of evidence-based education on prescribing in a psychiatry residency.
-
The impact of neuroleptic medication on tardive dyskinesia: a meta-analysis of published studies.
-
The inhibition of the kynurenine pathway prevents behavioral disturbances and oxidative stress in the brain of adult rats subjected to an animal model of schizophrenia.
-
The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients.
-
The ketogenic diet and remission of psychotic symptoms in schizophrenia: Two case studies.
-
The pharmacologic management of insomnia in patients with HIV.
-
The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine.
-
The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome.
-
The risk of anticholinergic toxicity in the elderly: a study of prescribing practices in two populations.
-
The sleep effects of lurasidone: a placebo-controlled cross-over study using a 4-h phase-advance model of transient insomnia.
-
The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients.
-
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
-
Time-lapse mapping of cortical changes in schizophrenia with different treatments.
-
Top Ten Tips Palliative Care Clinicians Should Know About Mental Health and Serious Illness.
-
Treatment algorithm use to optimize management of symptomatic patients with a history of mania.
-
Treatment of thyrotoxicosis-induced psychosis.
-
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
-
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
-
Tremorous mouth movements in rats administered chronic neuroleptics.
-
Unirhinal olfactory function in schizophrenia patients and first-degree relatives.
-
Unraveling interrelationships among psychopathology symptoms, cognitive domains and insight dimensions in chronic schizophrenia.
-
Use of aripiprazole in a patient with multiple sclerosis presenting with paranoid psychosis.
-
Use of lamotrigine in a patient with a clozapine-related seizure.
-
Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia.
-
Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia.
-
Ventral hippocampal alpha7 and alpha4beta2 nicotinic receptor blockade and clozapine effects on memory in female rats.
-
What CATIE found: results from the schizophrenia trial.
-
What are the new treatments for bipolar disorder?
-
Who are the new users of antipsychotic medications?
-
Working memory and schizophrenia: evidence for slowed encoding.
-
Ziprasidone-associated mania: a case series and review of the mechanism.
-
[Problem of neuronal reception and the dopamine hypothesis of schizophrenia].
-
Keywords of People
-
Bradford, Daniel William,
Professor of Psychiatry and Behavioral Sciences,
Psychiatry, Child & Family Mental Health & Community Psychiatry
-
Curtis, Lesley H.,
Professor in Population Health Sciences,
Medicine, General Internal Medicine
-
Olsen, Maren Karine,
Professor of Biostatistics & Bioinformatics,
Biostatistics & Bioinformatics
-
Wu, Li-Tzy,
Professor in Psychiatry and Behavioral Sciences,
Medicine, General Internal Medicine